Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adaptive Biotechnologies ( (ADPT) ) has issued an announcement.
On January 12, 2026, Adaptive Biotechnologies reported preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, highlighting strong growth across its MRD business led by adoption of its clonoSEQ test. Total revenue reached approximately $72 million for the quarter and $277 million for 2025, up 51% and 55%, respectively, from 2024, while MRD revenue rose to about $62 million in the quarter and $212 million for the year, representing gains of 54% and 46%; full-year MRD revenue excluding regulatory milestone payments grew 45%. clonoSEQ test volume climbed 43% to around 30,000 tests in the fourth quarter and 39% for the year to roughly 105,600 tests, and the company ended 2025 with about $227 million in cash, cash equivalents and marketable securities, excluding Digital Biotechnologies, Inc. cash, while cautioning that these figures are preliminary and subject to change as year-end closing and audits are completed and indicating that net loss is expected to narrow compared with 2024.
The most recent analyst rating on (ADPT) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Adaptive Biotechnologies stock, see the ADPT Stock Forecast page.
Spark’s Take on ADPT Stock
According to Spark, TipRanks’ AI Analyst, ADPT is a Neutral.
The score is held back primarily by weak profitability, negative ROE, and pressured cash flow trends despite strong revenue growth and healthy gross margins. Offsetting this, the latest earnings call showed meaningful MRD segment improvement (positive adjusted EBITDA/cash flow, reduced cash burn, and raised guidance). Technicals are neutral, while valuation signals risk due to losses (negative P/E) and no dividend support.
To see Spark’s full report on ADPT stock, click here.
More about Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company that harnesses the genetics of the adaptive immune system to develop clinical products for diagnosing, monitoring and treating diseases such as cancer and autoimmune disorders. Through its proprietary immune medicine platform, the company operates two main business segments—Minimal Residual Disease (MRD) and Immune Medicine—offering products like its clonoSEQ MRD test and partnering with biopharmaceutical firms to inform drug development and deliver immune-driven, patient-tailored diagnostics and therapies.
Average Trading Volume: 2,314,634
Technical Sentiment Signal: Buy
Current Market Cap: $2.44B
See more data about ADPT stock on TipRanks’ Stock Analysis page.